• 1
    Moore DF Jr., Cabanillas F. Overview of prognostic factors in non-Hodgkin's lymphoma. Oncology. 1998; 12(10 Suppl 8 ): 1724.
  • 2
    A predictive model for aggressive non-Hodgkin's lymphoma: the International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987994.
  • 3
    Jaffe ES, Harris NL, Stein H, Vordiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001.
  • 4
    National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982; 49: 21122135.
  • 5
    Rodriguez J, Cabanillas F, McLaughlin P, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the “tumor score”. Ann Oncol. 1992; 3: 711717.
  • 6
    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood. 1997; 89: 39093918.
  • 7
    Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1998; 16: 27802795.
  • 8
    Cox JD. Lymphomas and leukemia. In: CoxJD, editor. Moss' radiation oncology: rationale, technique, results. 7th ed. St. Louis: Mosby, 1994: 793826.
  • 9
    Non-Hodgkin's lymphoma. In: FlemingID, CooperJS, HensonDE, et al., editors. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven, 1997: 289294.
  • 10
    Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999; 17: 12441253.
  • 11
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 12
    Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977; 35: 139.
  • 13
    Horning SJ, Glick JH, Kim K, et al. Final report of E1484: CHOP v CHOP + radiotherapy (RT) for limited stage diffuse aggressive lymphoma [abstract]. Blood. 2001; 98: 724a.
  • 14
    Miller TP, Leblanc M, Spier C, Chase E, Fischer RI. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial [abstract]. Blood. 2001; 98: 724a.
  • 15
    Romaguera JE, Rodriquez Diaz-Pavon J, Carias L, et al. Use of the international prognostic index and the tumor score to detect poor-risk patients with primary mediastinal large B-cell lymphoma: a study of 37 previously untreated patients. Leuk Lymphoma. 1998; 28: 295306.
  • 16
    Rodriguez J, Pugh WC, Romaguera JE, et al. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol. 1994; 5: 847849.
  • 17
    Wilder RB, Rodriguez MA, Ha CS, et al. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer. 2001; 91: 24402446.
  • 18
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002; 346; 235242.
  • 19
    Sarris AH, Hagemeister F, Romaguera J, et al. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. Ann Oncol. 2000; 11: 6972.
  • 20
    Laport GF, Williams SF. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol. 1998; 25: 503517.
  • 21
    Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol — a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol. 2000; 18: 30253030.
  • 22
    Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503511.
  • 23
    Shipp M, Tamayo P, Angelo M, et al. Diffuse large B cell lymphoma outcome prediction by gene expression profiling [abstract]. Blood. 2001; 96: 222a.